Table 2.
Comparison of baseline and clinical characteristics on the basis of line of use of pablbociclib.
| Variable | Palbociclib + AI N = 115 | Palbociclib + fulvestrant N = 73 | p-value |
|---|---|---|---|
| Menopausal status | |||
| Pre/post | 61/54 | 47/26 | 0.125 |
| Sex | |||
| Transgender/male/female | 1/1/113 | 0/2/71 | 0.445 |
| Laterality | |||
| Right/left/bilateral | 52/61/2 | 39/31/3 | 0.274 |
| Stage at presentation | |||
| Early/locally advanced/metastatic | 16/20/79 | 29/26/18 | < 0.0001 |
| Brain metastasis | |||
| Present/absent | 7/108 | 2/71 | 0.295 |
| Site of metastasis | |||
| Visceral/bone only/lymph node only | 99/15/1 | 56/17/0 | 0.145 |
| Prior chemotherapy before palbociclib in the neoadjuvant/adjuvant setting | |||
| Yes/no | 41/17 | 54/16 | < 0.0001 |
| Response at first assessment | |||
| CR/PR/SD/PD | 7/85/16/7 | 2/33/12/26 | < 0.0001 |
| Dose variation | |||
| No/yes/discontinued/not known | 88/19/6/2 | 58/9/3/3 | 0.652 |
p-values in bold indicate statistical significance.